Biogen Inc (NASDAQ:BIIB) reported the engagement of Camille Lee as SVP, Alzheimer’s Therapeutic Area. In her new profile, Ms. Lee will look after the design and execution of commercial plan for the firm’s late-stage Alzheimer’s disease resources and will work in association with Biogen’s R&D function in overseeing company’s entire Alzheimer’s portfolio. She will report directly to CMO Alfred Sandrock, Jr., M.D., Ph.D. and will be based in Cambridge.
Biogen reported that Ms. Lee brings to company industry experience of over 30 years. In her recent role as SVP, Diabetes and Obesity Marketing at Novo Nordisk, she headed a team of over 500 professionals while managing the marketing of all future and in-line brands as well as market access plan. During her time in this role, Novo Nordisk successfully introduced two brands that recorded leadership in their therapeutic segments.
Dr. Sandrock added that Lee’s experience in preparing markets and introducing offerings for highly prevalent ailments will serve them well as they aspire to move toward commercializing their late-stage AD’s candidates. Her track record aligns well with their objective to deliver transformative treatments for neurodegenerative ailments to patients who desperately seek them.
Prior to serving on a leadership role for diabetes and obesity franchises with Novo Nordisk, Lee worked across the firm. Her tenure at Novo Nordisk comprised roles of increasing responsibility in distinct functions as competitor intelligence, product release planning, and global marketing for numerous endocrine products.
Ms. Lee expressed that Biogen’s R&D in AD’s is an inspiration, and she is delighted to be joining a firm that has such a steadfast commitment to the community. She looks forward to associating with the team as they intend to bring therapies to the industry that could make a difference to many patients and their families that the company serve.